Literature DB >> 28466283

Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.

Elif Hindié1, Charles Mesguich2, Krimo Bouabdallah3, Noël Milpied3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28466283     DOI： 10.1007/s00259-017-3714-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  32 in total

1.  Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Authors:  K Spaepen; S Stroobants; P Dupont; J Thomas; P Vandenberghe; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

2.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

6.  Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?

Authors:  K Strobel; N G Schaefer; C Renner; P Veit-Haibach; D Husarik; A Y Koma; T F Hany
Journal:  Ann Oncol       Date:  2007-02-17       Impact factor: 32.976

7.  18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.

Authors:  Mathieu Hatt; Mohamed Majdoub; Martin Vallières; Florent Tixier; Catherine Cheze Le Rest; David Groheux; Elif Hindié; Antoine Martineau; Olivier Pradier; Roland Hustinx; Remy Perdrisot; Remy Guillevin; Issam El Naqa; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2014-12-11       Impact factor: 10.057

8.  The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Authors:  Claudio Agostinelli; Andrea Gallamini; Luisa Stracqualursi; Patrizia Agati; Claudio Tripodo; Fabio Fuligni; Maria Teresa Sista; Stefano Fanti; Alberto Biggi; Umberto Vitolo; Luigi Rigacci; Francesco Merli; Caterina Patti; Alessandra Romano; Alessandro Levis; Livio Trentin; Caterina Stelitano; Anna Borra; Pier Paolo Piccaluga; Stephen Hamilton-Dutoit; Peter Kamper; Jan Maciej Zaucha; Bogdan Małkowski; Waldemar Kulikowski; Joanna Tajer; Edyta Subocz; Justyna Rybka; Christian Steidl; Alessandro Broccoli; Lisa Argnani; Randy D Gascoyne; Francesco d'Amore; Pier Luigi Zinzani; Stefano A Pileri
Journal:  Lancet Haematol       Date:  2016-10       Impact factor: 18.959

9.  Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET.

Authors:  Stefano Fanti; Paolo Castellucci; Vittorio Stefoni; Cristina Nanni; Monica Tani; Domenico Rubello; Valentina Ambrosini; Pier Luigi Zinzani; Roberto Franchi
Journal:  Ann Nucl Med       Date:  2008-07-04       Impact factor: 2.668

10.  CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.

Authors:  Annarosa Cuccaro; Salvatore Annunziata; Elisa Cupelli; Maurizio Martini; Maria L Calcagni; Vittoria Rufini; Manuela Giachelia; Francesca Bartolomei; Eugenio Galli; Francesco D'Alò; Maria T Voso; Giuseppe Leone; Alessandro Giordano; Luigi M Larocca; Stefan Hohaus
Journal:  Cancer Med       Date:  2016-01-13       Impact factor: 4.452
View more
  2 in total

1.  Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

Authors:  Elif Hindié; Charles Mesguich; Krimo Bouabdallah; Noël Milpied
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10       Impact factor: 9.236

2.  Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.